Diabetes & Insulin Resistance +
Familial Hypercholesterolemia (FH)

In FH, arteries are exposed to high LDL from birth. In diabetes: High glucose damages the endothelium, advanced glycation end products (AGEs) stiffen vessels, and oxidative stress increases. When combined, plaque forms faster and becomes more unstable. Patients with both conditions often show: Earlier coronary artery disease, multi-vessel involvement, and higher coronary calcium scores.

The endothelium regulates blood flow and prevents clot formation. Both FH and diabetes independently impair endothelial function. Together they: Increase oxidative stress, reduce nitric oxide production, and promote inflammation. This creates a vascular environment highly prone to plaque progression and clot formation.

While FH is primarily an LDL disorder, insulin resistance often produces: Elevated triglycerides, low HDL, and small dense LDL particles. Small dense LDL particles are particularly dangerous because they: Penetrate artery walls more easily, are more prone to oxidation, and trigger inflammation. This worsens the already elevated LDL burden in FH.

Studies show that individuals with FH who also develop type 2 diabetes have: Increased risk of myocardial infarction, higher likelihood of needing revascularization, and greater long-term cardiovascular mortality. The additive effect of LDL-driven plaque and glucose-driven vascular injury significantly raises event risk.

Even when LDL is aggressively lowered: Insulin resistance may persist, inflammation may remain elevated, and glucose variability continues to stress arteries. This means comprehensive management must address both lipid and metabolic health.

Interestingly, some research suggests that people with FH may have a slightly lower incidence of type 2 diabetes compared to the general population. Possible explanations include: Altered LDL receptor function and genetic metabolic differences. However, when diabetes does develop in FH patients — particularly due to obesity, sedentary lifestyle, or aging — cardiovascular risk becomes significantly elevated.

Statins are first-line therapy for FH. While statins slightly increase blood sugar levels in some individuals, the cardiovascular benefits overwhelmingly outweigh the small diabetes risk. For patients with both FH and diabetes: High-intensity statin therapy remains critical, LDL targets are often more aggressive (<55 mg/dL in very high risk patients), and stopping statins due to mild glucose elevation can be dangerous in FH.

Optimal care includes: Aggressive LDL Reduction (High-intensity statins, Ezetimibe, PCSK9 inhibitors, Inclisiran, LDL apheresis in severe cases); Glucose Control (Lifestyle modification, Metformin, GLP-1 receptor agonists, SGLT2 inhibitors which may also provide cardiovascular benefit); Inflammation Reduction (Weight management, Exercise, Blood pressure control). Comprehensive risk management is essential.

Patients with FH should routinely be screened for: Fasting glucose, HbA1c, and insulin resistance markers. Similarly, individuals with early heart disease and diabetes should be evaluated for possible FH if LDL levels exceed 190 mg/dL or there is a family history of premature cardiovascular disease.

The key concept in FH is cholesterol-year burden — cumulative lifetime LDL exposure. When diabetes or insulin resistance is added, vascular aging accelerates even further. Early diagnosis of FH allows: Earlier lipid control, prevention of metabolic complications, and family cascade screening. Reducing LDL early in life dramatically lowers long-term event risk — even in those who later develop diabetes.